Stage IV Endometrial Carcinoma Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028761 (Stage IV Endometrial Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006089Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerTreatment